{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:06:12Z","timestamp":1776326772777,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"BeiGene Aus Pty Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00277-024-05907-5","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T02:02:11Z","timestamp":1722909731000},"page":"3615-3625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea"],"prefix":"10.1007","volume":"103","author":[{"given":"Seok Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seug Yun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeran","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junice","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"issue":"4","key":"5907_CR1","first-page":"1262","volume":"52","author":"JS Kim","year":"2020","unstructured":"Kim JS, Liu Y, Ha KH, Qiu H, Rothwell LA, Kim HC (2020) Increasing incidence of B-cell non-Hodgkin lymphoma and occurrence of second primary malignancies in South Korea: 10-Year follow-up using the Korean National Health Information Database. Cancer Res Treat 52(4):1262\u20131272","journal-title":"Cancer Res Treat"},{"key":"5907_CR2","unstructured":"Jamil AMS, Lymphoma In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan 2022; 2022 [updated 18 July 2022] https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560826\/"},{"issue":"S1","key":"5907_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5045\/br.2022.2022054","volume":"57","author":"SH Jeong","year":"2022","unstructured":"Jeong SH (2022) Treatment of indolent lymphoma. Blood Res 57(S1):120\u2013129","journal-title":"Blood Res"},{"issue":"12","key":"5907_CR4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ajh.21557","volume":"84","author":"SY Oh","year":"2009","unstructured":"Oh SY, Kim WS, Kim SJ, Kim JS, Kim SH, Lee DH et al (2009) Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Am J Hematol 84(12):826\u2013829","journal-title":"Am J Hematol"},{"issue":"11","key":"5907_CR5","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","volume":"19","author":"AD Zelenetz","year":"2021","unstructured":"Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH et al (2021) NCCN guidelines insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw 19(11):1218\u20131230","journal-title":"J Natl Compr Canc Netw"},{"key":"5907_CR6","unstructured":"NCCN Guidelines Insights B-Cell Lymphomas, Version 2.2024 [https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480]; 21 May 2024"},{"key":"5907_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijerph17196938","volume":"17","author":"A Lewandowska","year":"2020","unstructured":"Lewandowska A, Rudzki G, Lewandowski T, Pr\u00f3chnicki M, Rudzki S, Laskowska B et al (2020) Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health 17:19","journal-title":"Int J Environ Res Public Health"},{"key":"5907_CR8","unstructured":"Resemann HK, Clements SJ, Griffiths A, Sheard D Reporting of Delphi methods to achieve consensus on guidelines in rare diseases. European meeting of the International Society for Medical Publication Professionals (ISMPP) 23\u201324 January; London, UK. 2018."},{"issue":"4","key":"5907_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","volume":"32","author":"F Hasson","year":"2000","unstructured":"Hasson F, Keeney S, McKenna H (2000) Research guidelines for the Delphi survey technique. J Adv Nurs 32(4):1008\u20131015","journal-title":"J Adv Nurs"},{"issue":"7001","key":"5907_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","volume":"311","author":"J Jones","year":"1995","unstructured":"Jones J, Hunter D (1995) Consensus methods for medical and health services research. BMJ 311(7001):376\u2013380","journal-title":"BMJ"},{"issue":"1","key":"5907_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12094-022-02941-5","volume":"25","author":"D Isla","year":"2023","unstructured":"Isla D, Felip E, Garrido P, Insa A, Majem M, Remon J et al (2023) A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study. Clin Transl Oncol 25(1):283\u2013291","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"5907_CR12","first-page":"41","volume":"6","author":"C Duffield","year":"1988","unstructured":"Duffield C (1988) The Delphi technique. Aust J Adv Nurs 6(2):41\u201345","journal-title":"Aust J Adv Nurs"},{"key":"5907_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1471-2288-5-37","volume":"5","author":"RB Akins","year":"2005","unstructured":"Akins RB, Tolson H, Cole BR (2005) Stability of response characteristics of a Delphi panel: application of bootstrap data expansion. BMC Med Res Methodol 5:37","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"5907_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.2021.278755","volume":"107","author":"CY Cheah","year":"2022","unstructured":"Cheah CY, Zucca E, Rossi D, Habermann TM (2022) Marginal zone lymphoma: present status and future perspectives. Haematologica 107(1):35\u201343","journal-title":"Haematologica"},{"issue":"1","key":"5907_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","volume":"31","author":"E Zucca","year":"2020","unstructured":"Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M et al (2020) Marginal zone lymphomas: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(1):17\u201329","journal-title":"Ann Oncol"},{"key":"5907_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/CMAR.S133291","volume":"10","author":"NM Denlinger","year":"2018","unstructured":"Denlinger NM, Epperla N, William BM (2018) Management of relapsed\/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Manag Res 10:615\u2013624","journal-title":"Cancer Manag Res"},{"issue":"1","key":"5907_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1182\/hematology.2020000157","volume":"2020","author":"A Broccoli","year":"2020","unstructured":"Broccoli A, Zinzani PL (2020) How do we sequence therapy for marginal zone lymphomas? Hematol Am Soc Hematol Educ Program 2020(1):295\u2013305","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"5907_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","volume":"91","author":"HJ Kang","year":"2012","unstructured":"Kang HJ, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS et al (2012) Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol 91(4):543\u2013551","journal-title":"Ann Hematol"},{"issue":"15","key":"5907_CR19","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","volume":"130","author":"A Salar","year":"2017","unstructured":"Salar A, Domingo-Domenech E, Panizo C, Nicol\u00e1s C, Bargay J, Munta\u00f1ola A et al (2017) Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood 130(15):1772\u20131774","journal-title":"Blood"},{"issue":"7","key":"5907_CR20","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1182\/bloodadvances.2021006844","volume":"6","author":"JP Alderuccio","year":"2022","unstructured":"Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N et al (2022) An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv 6(7):2035\u20132044","journal-title":"Blood Adv"},{"issue":"9873","key":"5907_CR21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210","journal-title":"Lancet"},{"issue":"19","key":"5907_CR22","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944\u20132952","journal-title":"Blood"},{"issue":"1","key":"5907_CR23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/hematology.2022000362","volume":"2022","author":"M Merli","year":"2022","unstructured":"Merli M, Arcaini L (2022) Management of marginal zone lymphomas. Hematology 2022(1):676\u2013687","journal-title":"Hematology"},{"issue":"23","key":"5907_CR24","doi-asserted-by":"publisher","first-page":"6323","DOI":"10.1158\/1078-0432.CCR-21-1704","volume":"27","author":"S Opat","year":"2021","unstructured":"Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H et al (2021) The MAGNOLIA trial: Zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma. Clin Cancer Res 27(23):6323\u20136332","journal-title":"Clin Cancer Res"},{"issue":"2","key":"5907_CR25","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1002\/ffo2.144","volume":"5","author":"PD Andersen","year":"2023","unstructured":"Andersen PD (2023) Constructing Delphi statements for technology foresight. Futures Foresight Sci 5(2):e144","journal-title":"Futures Foresight Sci"}],"updated-by":[{"DOI":"10.1007\/s00277-024-06082-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05907-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05907-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T02:03:29Z","timestamp":1732241009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05907-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5907"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05907-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"12 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-024-06082-3","URL":"https:\/\/doi.org\/10.1007\/s00277-024-06082-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SJK and SYY report consulting fees from BeiGene, during the conduct of the study. JK, JN, and HB are employed by BeiGene. SC is employed by IQVIA. This study was supported by BeiGene Aus Pty Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}